000112151 001__ 112151
000112151 005__ 20230519145452.0
000112151 0247_ $$2doi$$a10.1038/s41419-021-04420-1
000112151 0248_ $$2sideral$$a126004
000112151 037__ $$aART-2021-126004
000112151 041__ $$aeng
000112151 100__ $$aSoriano-Teruel, Paula M.
000112151 245__ $$aIdentification of an ASC oligomerization inhibitor for the treatment of inflammatory diseases
000112151 260__ $$c2021
000112151 5060_ $$aAccess copy available to the general public$$fUnrestricted
000112151 5203_ $$aThe ASC (apoptosis-associated speck-like protein containing a caspase recruitment domain (CARD)) protein is an scaffold component of different inflammasomes, intracellular multiprotein platforms of the innate immune system that are activated in response to pathogens or intracellular damage. The formation of ASC specks, initiated by different inflammasome receptors, promotes the recruitment and activation of procaspase-1, thereby triggering pyroptotic inflammatory cell death and pro-inflammatory cytokine release. Here we describe MM01 as the first-in-class small-molecule inhibitor of ASC that interferes with ASC speck formation. MM01 inhibition of ASC oligomerization prevents activation of procaspase-1 in vitro and inhibits the activation of different ASC-dependent inflammasomes in cell lines and primary cultures. Furthermore, MM01 inhibits inflammation in vivo in a mouse model of inflammasome-induced peritonitis. Overall, we highlight MM01 as a novel broad-spectrum inflammasome inhibitor for the potential treatment of multifactorial diseases involving the dysregulation of multiple inflammasomes.
000112151 536__ $$9info:eu-repo/grantAgreement/EC/FP7/614578/EU/Regulation of inflammatory response by extracellular ATP and P2X7 receptor signalling: through and beyond the inflammasome/Danger ATP$$9info:eu-repo/grantAgreement/ES/MINECO/SAF2018-88276-R
000112151 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000112151 590__ $$a9.696$$b2021
000112151 592__ $$a2.099$$b2021
000112151 594__ $$a13.5$$b2021
000112151 591__ $$aCELL BIOLOGY$$b36 / 195 = 0.185$$c2021$$dQ1$$eT1
000112151 593__ $$aCancer Research$$c2021$$dQ1
000112151 593__ $$aMedicine (miscellaneous)$$c2021$$dQ1
000112151 593__ $$aImmunology$$c2021$$dQ1
000112151 593__ $$aCell Biology$$c2021$$dQ1
000112151 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000112151 700__ $$aGarcia-Lainez, Guillermo
000112151 700__ $$aMarco-Salvador, María
000112151 700__ $$0(orcid)0000-0003-0154-0730$$aPardo, Julián$$uUniversidad de Zaragoza
000112151 700__ $$aArias, Maykel
000112151 700__ $$aDeFord, Christian
000112151 700__ $$aMerfort, I
000112151 700__ $$aVicent, María J.
000112151 700__ $$aPelegrin, Pablo
000112151 700__ $$aSancho, Mónica
000112151 700__ $$aOrzaez, Mar
000112151 7102_ $$11011$$2566$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Inmunología
000112151 773__ $$g12 (2021), [11 pp.]$$pCell death dis.$$tCELL DEATH & DISEASE$$x2041-4889
000112151 8564_ $$s3202946$$uhttps://zaguan.unizar.es/record/112151/files/texto_completo.pdf$$yVersión publicada
000112151 8564_ $$s2960896$$uhttps://zaguan.unizar.es/record/112151/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000112151 909CO $$ooai:zaguan.unizar.es:112151$$particulos$$pdriver
000112151 951__ $$a2023-05-18-14:46:59
000112151 980__ $$aARTICLE